Clinical Trial Update: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 trial assessing infectivity, safety, and immunogenicity of a recombinant live-attenuated RSV vaccine in seronegative infants; study terminated with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV LID cp ΔM2-2 (recombinant live-attenuated Respiratory Syncytial Virus vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: TERMINATED | Results posted: 2018-07-02